Results suggest olanzapine should be a standard to reduce chemotherapy-induced nausea and vomiting
Kenrick Ng, Barts Health NHS Trust shared a post on X by Yüksel Ürün:
“Evidence for using olanzapine, an effective and cost friendly antiemetic, is robust but very underused in U.K.
We have also demonstrated how using olanzapine in a steroid-sparing protocol reduces rates of neutropenic sepsis in GCT patients”
Authors: Ernese Gjafa, Kenrick Ng, Tami Grunewald, Myria Galazi, Erik Skyllberg, Peter Wilson, Constantine Alifrangis, Jonathan Shamash
Quoting Yüksel Ürün’s post:
“In a phase 3 trial (Again and again…) with 560 patients, adding olanzapine to dexamethasone, palonosetron, and aprepitant increased complete response rates from 82% to 91%.
Results suggest olanzapine should be a standard to reduce chemotherapy-induced nausea and vomiting (CINV).”
Source: Kenrick Ng/X and Yüksel Ürün/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023